The video interview features John Tomtishen, Catalent’s Global Head of Cell Therapy Field Application Scientists and Strategic Alliances.
2
Tomtishen discusses his career and changes he has witnessed across the cell therapy field.
3
He explains why developers should prioritize product characterization early in development.
4
Tomtishen also emphasizes the importance of addressing chemistry, manufacturing, and controls early in development.
5
He discusses technologies and manufacturing strategies that could improve scalability and the industry’s efforts to bring future cell therapies to more patients.
